Now that automated slide making has been adopted in leading institutions around the world, we can better quantify its impact on the laboratory. Beyond the obvious benefits of reproducibility and reduced hands-on time, automated platforms for slide making offer a new level of digitalization that has changed the way managers and directors understand their workflows. Systems that now monitor the ‘life-cycle of the slide’ make this information readily available to everyone in the lab as well as other key automated systems (automated scanners and LIS platforms).
Automation has also allowed labs to work with slide configurations that use less reagent and sample, all while delivering on the most important metrics – quality and consistency. By allowing laboratories to perform more assays per slide, we now have tools available to us that are having a profound effect on lab economics and turnaround times.
Our presentation will look closely at key metrics that are influenced by automation, the overall value of these improvements, and strategies for building a new digital infrastructure in your laboratory.
As a member of the original team who developed the patented FISHArray technology in the early 2000’s, Brian now leads the Molecular Diagnostics business unit within BioDot, where he leverages BioDot’s expertise in high throughput nanoprinting technology to commercialize important tools for the cytogenetics and molecular diagnostics community.
Brian has over 15 years of experience designing, developing, and marketing high throughput manufacturing systems for many of the world’s largest diagnostic companies.